Albers Jeffrey W.
Spyre Therapeutics, Inc. · Director
Albers Jeffrey W. is listed in filings as Director at Spyre Therapeutics, Inc.. This profile follows SEC Form 4 activity through May 29, 2026, including sale activity. Recent filings connect the profile to Spyre Therapeutics, Inc. (SYRE), Kymera Therapeutics, Inc. (KYMR), and Blueprint Medicines Corporation (BPMC). The current snapshot covers public activity from Aug 26, 2024 to May 29, 2026. Reported amounts are shown as $10.9K to $388.8K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.